Irina Bilous

Artificial Intelligence (AI) is steadily making its presence felt across various sectors, including the pharmaceutical industry. Among the multiple applications of AI in this field, immunotherapy - a treatment method that utilizes the body's immune system to combat diseases, notably …

Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for CNS assets from phase 1 through to regulatory submission was only 5–6%.

The failure of pharmaceutical companies to bring CNS …

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials …

The fusion of artificial intelligence (AI) with multi-omics - a comprehensive study encompassing genomics, transcriptomics, proteomics, metabolomics, and other related fields - is heralding an era of speedier, more efficient drug discovery. AI has been disrupting various sectors, but its …

Verge Genomics, a frontrunner in the implementation of AI in drug discovery, recently concluded the Phase 1 clinical trial of VRG50635, an investigational drug for Amyotrophic Lateral Sclerosis (ALS). The drug, developed through artificial intelligence-driven methods, was well tolerated and …

IgGenix, Inc., a California-based preclinical antibody discovery and development company, recently reported advances towards a potential therapeutic solution for peanut allergies based on IgG4 monoclonal antibodies.

Certara, a leader in biosimulation, has recently expanded the horizons of AI in drug discovery with the introduction of artificial intelligence (AI) capabilities and data fabric connectivity to its clinical trials outcome analytics platform, CODEX.

Seqera Labs, recognized for its secure workflow orchestration software in the life sciences domain, is aligning forces with Genomics England, a government-owned entity, which initiated the notable 100,000 Genomes Project in alliance with the NHS. This collaboration aims to enhance …

Valo Therapeutics Oy (ValoTx), a frontrunner in the development of advanced immunotherapies for cancer, has initiated its Phase I trial of PeptiCRAd-1, a pioneer in the realm of immuno-oncology. The first participant, enrolled in this Germany-based trial, has received the …

PharmEnable, an innovative drug discovery firm, recently secured $7.5M in Pre-Series A financing, reflecting growing confidence in its proprietary AI-based drug discovery platform and potential contributions to the treatment of cancer and neurological diseases. This move signifies the latest milestone …